[PHP57] Impact Of Advanced Therapy Medicinal Products Cost On Public Health Care Budgets

[PHP57] Impact Of Advanced Therapy Medicinal Products Cost On Public Health Care Budgets

2014 Value in health

Toumi, M. | Kornfeld, A. | Charaf, A. | Volume: 17, Issue: 3, Pages: A19, t,

Advanced Therapy Medicinal Products (ATMPs) include innovative and regenerative therapies such as gene therapy, somatic cell therapy medicinal product, and tissue engineered product. They represent major opportunity for curing many chronic disabling diseases. About 300 clinical trials for ATMPs are ongoing. Should some of these therapies reach their goal, which is considered to be likely, the impact on already constraint public payer budget would be dramatic. The objective of this project was to assess yearly cost of ATMPs for payers assuming a pay for performance split over years as long as disease do not re-emerge.